ERBB2 and glioblastoma: Burger et al. [107] conducted a phase I first‐in‐human clinical trial to assess the safety and feasibility of the adoptive transfer of clonal CAR‐NK cells (NK‐92/5.28.z) targeting HER2, which is overexpressed in a subset of GBM.